Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Alnylam; Alcon; Thermo Fisher; and More

Premium

Title: Oncogenic ALL-1 Fusion Proteins for Targeting Drosha-Mediated microRNA Processing

Patent Number: 8,053,186

Filed: June 13, 2008

Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, comprises “compositions and methods for reducing the proliferation of [acute lymphomic leukemia] cancer cells through targeted interactions with ALL1 fusion proteins.”


Title: dsRNA Delivery Composition and Methods of Use

Application Number: 20110268691

Filed: May 3, 2011

Lead Inventor: Blair Siegfried, University of Nebraska

The invention, the patent application's abstract states, provides for “compositions comprising a cucurbitacin bait for stimulating insect feeding and a dsRNA … for eliciting RNAi-mediated gene silencing in an insect. The ... invention also provides for methods of delivering a dsRNA molecule to an insect, inhibiting protein expression in an insect, and killing an insect by providing a dsRNA molecule.”


Title: Gene Silencing by Single-Stranded Polynucleotides

Application Number: 20110269813

Filed: Feb. 1, 2008

Inventor: Gretchen Unger, Genesegues

The invention relates to “compositions and methods for concurrently activating antisense and double-stranded RNase mechanisms for inhibiting expression of a targeted gene, by delivering a single stranded bifunctional chimeric DNA/RNA oligonucleotide optimized for siRNA activity, as well as antisense activity, into the nucleus of a target cell,” according to the patent application's abstract.


Title: 2'-F-Modified RNA Interference Agents

Application Number: 20110269814

Filed: March 26, 2009

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

“This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent … [made up of] at least one 2'-deoxy-2'-fluoro nucleotide in the antisense strand and at least one modified nucleotide in the sense strand,” the patent application's abstract states. “The invention also relates to compositions comprising a single-stranded oligonucleotide that contains at least one 2'-deoxy-2'-fluoro nucleotide." The abstract adds that siRNA molecules containing these oligonucleotides "have decreased immunogenicity.”


Title: Inhibition of Viral Gene Expression Using Small Interfering RNA

Application Number: 20110269816

Filed: March 2, 2011

Lead Inventor: Roger Kaspar, SomaGenics

“The invention provides methods, compositions, and kits comprising small interfering RNA that are useful for inhibition of viral-mediated gene expression,” according to the patent application's abstract. “Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targeting the internal ribosome entry site sequence of HCV are described.”


Title: RNAi-Mediated Inhibition of Histamine Receptor H1-Related Conditions

Application Number: 20110269822

Filed: June 30, 2011

Lead Inventor: John Yanni, Alcon

The invention, the patent application's abstract states, comprises “RNA interference … for [the] inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.”


Title: Compositions and Methods for Inhibiting Expression of the HAMP Gene

Application Number: 20110269823

Filed: July 15, 2011

Lead Inventor: Tomoko Nakayama, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the HAMP gene comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length … and which is substantially complementary to at least a part of the HAMP gene,” the patent application's abstract states. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by HAMP gene expression, and the expression of the HAMP gene using the pharmaceutical composition.”


Title: siRNA Targeting Cyclin-Dependent Kinase Inhibitor 1B

Application Number: 20110269951

Filed: July 5, 2011

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for CDKN1B.”

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.